A detailed history of Gilder Gagnon Howe & CO LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 19,589 shares of RARE stock, worth $889,340. This represents 0.01% of its overall portfolio holdings.

Number of Shares
19,589
Previous 19,927 1.7%
Holding current value
$889,340
Previous $818,000 33.01%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.21 - $59.36 $13,590 - $20,063
-338 Reduced 1.7%
19,589 $1.09 Million
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $93,699 - $129,231
2,504 Added 14.37%
19,927 $818,000
Q1 2024

May 15, 2024

SELL
$43.02 - $53.69 $7,614 - $9,503
-177 Reduced 1.01%
17,423 $813,000
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $254,093 - $393,913
8,008 Added 83.49%
17,600 $841,000
Q3 2023

Nov 14, 2023

SELL
$34.92 - $46.66 $1,955 - $2,612
-56 Reduced 0.58%
9,592 $341,000
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $360,352 - $503,143
9,648 New
9,648 $445,000
Q2 2022

Aug 15, 2022

SELL
$45.8 - $85.4 $77,997 - $145,436
-1,703 Reduced 25.23%
5,048 $301,000
Q1 2022

May 16, 2022

SELL
$62.2 - $84.4 $453,002 - $614,685
-7,283 Reduced 51.9%
6,751 $490,000
Q4 2021

Feb 14, 2022

SELL
$73.71 - $87.86 $296,756 - $353,724
-4,026 Reduced 22.29%
14,034 $1.18 Million
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $22,129 - $29,081
-284 Reduced 1.55%
18,060 $1.63 Million
Q2 2021

Aug 16, 2021

SELL
$92.19 - $115.71 $4,056 - $5,091
-44 Reduced 0.24%
18,344 $1.75 Million
Q1 2021

May 17, 2021

SELL
$106.9 - $167.73 $523,382 - $821,206
-4,896 Reduced 21.03%
18,388 $2.09 Million
Q4 2020

Feb 16, 2021

BUY
$84.4 - $177.39 $1.97 Million - $4.13 Million
23,284 New
23,284 $3.22 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.